A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis

Merck Sharp & Dohme (MSD)

Status: Completed

Conditions: Candidiasis, Esophageal; HIV Infections

Treatments: Drug: L-743,872

Study type: Interventional

Funder types: Industry

Identifiers

NCT00005921

007-00

267A

Details and patient eligibility

About

The purpose of this study is to see if it is safe to give L-743,872 to men with candidal esophagitis, an AIDS-related yeast infection in the esophagus.

Full description

In this open-label study, patients receive intravenous L-743,872 every 24 hours at one of three dose levels for 14 days. Post-study safety evaluations continue for 4 weeks after the final dose. Pharmacokinetics and safety measurements are taken throughout the 6-week study.

Sex: Male

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

You may be eligible for this study if you:

• Are an 18- to 65-year-old man with candidal esophagitis.